You searched for "registrar"

511 results found

Urological emergencies app

BrainyDoc Ltd is back with another brand new educational app called ‘Urological Emergencies’. It is available as a free download for iPhone and iPad (iTunes) and Android mobile devices (Google Play). The Urological Emergencies app provides a series of topics...

BAUS 2024 - Welcome from the Honorary Secretary

Joe Philip. I am thrilled to extend a warm welcome to each and every one of you as we gear up for what promises to be an enriching and enlightening conference experience. On behalf of Mo Belal, the remarkable events...

‘No Deal’ Brexit – how might it impact urological practice in the UK?

On 29 March 2017, the Government of the United Kingdom of Great Britain & Northern Ireland triggered Article 50 of the Lisbon Treaty, formally starting the two-year period for talks with the European Union (EU) in which to reach a...

Abiraterone acetate in men with castration-resistant prostate cancer

With emerging results from the Stampede and Latitude studies, abiraterone has taken the forefront in the management of metastatic prostate cancer while researchers try to identify the ideal timing for administration. It is a potent inhibitor of CYP17 which results...

Radium-223 treatment outcomes after multiple lines of mCRPC therapy in clinical practice: implication of pre-treatment spinal epidural disease

There are a number of treatments now available to patients with metastatic castrate-resistant prostate cancer (mCRPC). However, the optimal timing and order in which they are given is less clear. Radium-223 was FDA-approved for mCRPC patients with symptomatic bone metastases...

Predicting bone scan positivity in non-metastatic CRPC

There is evidence that suggests that early treatment with chemotherapy, immunotherapy or hormone therapy leads to a better response in patients with asymptomatic metastatic castrate resistant prostate cancer (CRPC). This study aimed to predict bone scan positivity in patients with...

The potential of statin use in castrate resistant prostate cancer treatment

One of the mechanisms by which prostate cancer achieves castrate resistance is through de novo intratumoral production of androgens. Reactivation of androgen receptors results in promotion of cell survival and proliferation pathways despite castrate serum testosterone levels. As androgen synthesis...

ACP (Association for Continence Professionals) Annual Conference 2025

The main programme will be of interest to, Bladder and Bowel Nurses, Physiotherapists, Occupational Therapists, Urology Nurses, and Specialist Nurses as well as Doctors, Nurses and Allied Healthcare Professionals working within, or interested in Continence Care.

Bladder Health UK – Patient Support Charity

Since its beginnings as an Interstitial Support Group back in 1994 Bladder Health UK has developed and grown into a well-respected provider of support, expertise and education to both patients and healthcare professionals. The charity's ambition is to continue to...

Giggle incontinence – not a laughing matter!

For many decades, the condition of giggle incontinence (enuresis risoria, giggle micturition) has remained a rare and poorly understood condition. Patients (90% female) present in their teens, with the history revealing an issue for many years. It is debilitating and...

Trials offering cytoreductive surgery for men with de novo synchronous metastatic prostate cancer

Life expectancy in men diagnosed with de novo synchronous metastatic hormone-sensitive prostate cancer (mHSPC) has risen to a median of 4.8 years with upfront systemic agents (such as docetaxel) in addition to standard androgen deprivation therapy (ADT) [1-3]. Within this...

Urodynamics in review: stress urinary incontinence in women produced by the Urodynamics Committee of the ICS

Urodynamic studies (UDS) are the best tools to objectively assess the lower urinary tract dysfunction (LUTD) of various aetiologies [1]. According to the general understanding and consensus of the medical community UDS should be performed only when they will change...